Camurus AB (publ) (STO:CAMX)

Market Cap	37.68B
Revenue (ttm)	1.87B
Net Income (ttm)	428.39M
Shares Out	58.64M
EPS (ttm)	7.20
PE Ratio	89.24
Forward PE	36.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	78,467
Average Volume	85,481
Open	657.50
Previous Close	657.00
Day's Range	635.50 - 657.50
52-Week Range	437.40 - 715.00
Beta	1.01
RSI	61.94
Earnings Date	Feb 13, 2025

About Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1991
• Employees: 256
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CAMX

Financial Performance

In 2024, Camurus AB's revenue was 1.87 billion, an increase of 8.78% compared to the previous year's 1.72 billion. Earnings were 428.39 million, a decrease of -0.71%.